A number that could change your prognosis conversation
Before surgery for colorectal cancer, doctors draw blood. They check dozens of markers. Two of those markers — albumin (a protein that reflects nutrition and liver health) and CEA (carcinoembryonic antigen, a substance often elevated in colorectal cancer) — are already routine. What researchers found is that the ratio between them may say far more than either test alone.
Why colorectal cancer prognosis is still imprecise
Colorectal cancer is one of the most common cancers worldwide. Each year, hundreds of thousands of people undergo surgery to remove tumors. After surgery, doctors use a system called TNM staging — based on tumor size, lymph node involvement, and spread — to estimate how likely the cancer is to return and how aggressively to treat it.
But TNM staging has limits. Two patients at the same stage can have very different outcomes. For years, doctors have searched for additional markers that could fill in the gaps.
Old tools versus a sharper lens
The standard approach says: look at how far the cancer has spread. Stage I through IV tells you a lot, but it misses factors like the patient's overall nutritional state and the tumor's biological activity.
Here is what is new: by dividing the albumin level by the CEA level before surgery, researchers created a single number — the ACR — that appears to capture some of what staging misses. A low ACR may signal a body under stress and a tumor behaving aggressively, even when the stage alone does not tell that story.
Why these two markers make sense together
Albumin is like a report card for overall body health. Low albumin suggests the body is nutritionally depleted or struggling — a known risk factor for poor cancer outcomes. CEA, on the other hand, is a signal the tumor sends out. Higher CEA often means a more active or larger cancer.
Putting them in a ratio creates a balance score. High albumin relative to CEA suggests a healthier body facing a less active cancer. Low albumin relative to high CEA paints a more concerning picture.
Think of it like a seesaw — when health markers go down and cancer signals go up, the balance tips toward worse outcomes.
Inside the study
Researchers analyzed data from 966 patients with colorectal cancer who underwent radical surgery at a cancer center in China between January and December 2017. All patients were followed over time to track overall survival (OS) and disease-free survival (DFS — meaning how long until cancer returned).
Patients in the low ACR group — representing about 15% of the study — had significantly worse survival outcomes. Both overall survival and disease-free survival were dramatically lower compared to the high ACR group (p<0.001 for both — a statistical result that is extremely unlikely to be due to chance).
Even after accounting for other factors like age, tumor stage, and treatment type, a high ACR remained an independent protective factor. Patients with high ACR were more than twice as likely to survive overall compared to those with low ACR.
The team then built a prediction tool — called a nomogram — that combines ACR with other clinical factors to estimate an individual patient's risk. This tool outperformed standard TNM staging in accuracy, with a concordance index (a measure of predictive accuracy) of 0.786 for overall survival versus lower values for TNM staging alone.
This means the tool could help identify high-risk patients who might benefit from more aggressive follow-up or additional treatment — before problems arise.
Fitting into the bigger picture
Oncologists have increasingly moved toward personalized risk assessment — moving beyond one-size-fits-all staging. Tools that use readily available blood markers to sharpen prognosis are especially attractive because they do not require expensive new tests or equipment.
The ACR is calculated from tests already ordered for most surgical patients, which means this approach could be adopted widely without adding cost or complexity.
If you or a loved one is scheduled for colorectal cancer surgery, this research is not yet standard practice — but it may be worth asking your oncologist whether your albumin and CEA levels will be measured preoperatively and how they factor into your risk assessment.
Routine blood work may carry more prognostic weight than previously understood.
Limitations to keep in mind
This was a retrospective study — researchers looked back at past records rather than following patients forward. All patients were treated at a single center in China, which limits how widely the results can be applied to other populations or healthcare systems. The nomogram also needs validation in larger, more diverse cohorts before it can be recommended for routine clinical use.
Researchers are calling for prospective studies — ones that follow new patients forward from the time of diagnosis — to validate the ACR nomogram in different settings. If results hold up across populations, this ratio could eventually become a standard part of preoperative assessment for colorectal cancer, helping doctors and patients make more informed decisions about treatment intensity and surveillance planning.